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Oxidative stress and disorders in calcium balance play a crucial role in the doxorubicin-induced cardiotoxicity. Moreover, many
cardiotoxic targets of doxorubicin are regulated by iodothyronine hormones. The aim of the study was to evaluate eﬀects of
tetraiodothyronine (0.2, 2mg/L) on oxidative stress in the cardiac muscle as well as contractility and cardiomyocyte damage
markers in rats receiving doxorubicin (1.5mg/kg) once a week for ten weeks. Doxorubicin was administered alone (DOX)
or together with a lower (0.2T4 + DOX) and higher dose of tetraiodothyronine (2T4 + DOX). Two groups received only
tetraiodothyronine(0.2T4,2T 4).Coadministrationoftetraiodothyronineanddoxorubicinincreasedtheleveloflipidperoxidation
products and reduced RyR2 level when compared to untreated control and group exposed exclusively to doxorubicin. Insigniﬁcant
diﬀerences in SERCA2 and occasional histological changes were observed. In conclusion, an increase of tetraiodothyronine level
may be an additional risk factor of redox imbalance and RyR2 reduction in anthracycline cardiotoxicity.
1.Introduction
Doxorubicin (DOX) is one of the widely used antitumor
drugs, but its cumulative cardiac toxicity has been a major
concern for oncologists [1–5]. The analysis of the main
mechanisms responsible for DOX cardiotoxicity, oxidative
stress [6, 7], and cardiac contractility disorders [8–10] indi-
catesthatsomeofthemmaybetargetedbythyroidhormones
(THs). Therefore, it seems that hyperthyreosis may by an
additional risk factor in anthracycline cardiotoxicity.
There is an increasing body of evidence that the synthesis
of many molecules involved in the heart systole and diastole
is regulated during transcription by THs [11, 12]. Such an
eﬀect was proved for the expression of ryanodine receptor
(RyR2) and cardiac sarcoplasmic reticulum Ca2+ ATP-are
(SERCA2), which are responsible for the heart systole and
diastole, respectively [13, 14]. Moreover, THs generate react-
ive oxygen species (ROS) which are signaling molecules in
the regulation of RyR2 and SERCA2 functions [15–18].
ROS oversynthesis [19, 20] is mediated by active
metabolites of thyroxine (T4): (3,3 -5) triiodothyronine
(T3) and diiodothyronine (3,5-T2) in a short-term mech-
anism due to allosteric activation of cytochrome c oxidase
[21, 22]a n dT 3-dependent long-term signalling inducing
synthesis of enzymes involved in mitochondrial function,
for example, respiratory chain proteins. This results in
acceleration of the mitochondrial consumption of O2 [23]
and, consequently, an enhanced generation of superoxide
and H2O2 [24]. T3-dependent ROS oversynthesis [25, 26]
may also increase due to the transcriptional activation of2 Oxidative Medicine and Cellular Longevity
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Figure 1: A schedule of drug administration (DOX-doxorubicin, T4-tetraiodothyonine).
NADPH-dependent enzymes: cytochrome P450 reductase
(P450R) [19, 27, 28], oxidase [23], and nitric oxide synthase
(NOS) [29]. Iodothyronine hormones also control the
production of key enzymes responsible for the synthesis of
NADPH, which is essential for the oxidative stress defense
in the glutathione regeneration mechanism [30–32]. It
should be stressed that NADPH is a source of ROS (as a
cofactor of P450R, NOS and NADPH oxidase) and at the
same time an indispensable factor in antioxidative stress
defense.
DOX may elicit cardiotoxicity which becomes evident
even many years after chemotherapy is completed and which
may result in death [4, 5]. ROS generation in the presence of
DOX is strictly connected with one electron reduction cat-
alyzed by NADPH-dependent enzyme controlled by T4 [33–
36] and others [37–39]. On the other hand, the disturbance
in the cardiac contractility produced by DOX might be at
least partly related to changes in the expressions and activity
of RyR2 and SERCA2 [9, 40].
The fact that the expression of some genes encoding
proteins responsible for the cardiac muscle contractility and
for the regulation of key enzymes involved in redox balance
is aﬀected by iodothyronine hormones suggests that the
eﬀect of anthracyclines on these processes may diﬀer in
hyperthyroid and euthyroid individuals. Therefore, it might
be of clinical importance if a high level of iodothyronine
hormones is or is not a risk factor for anthracycline
cardiotoxicity. The aim of the present study was to evaluate
theeﬀectofdietsupplementedwithT4 onRyR2andSERCA2
protein level and on markers of cardiac redox imbalance and
the incidence of necrosis of cardiomyocytes in rats receiving
doxorubicin.
2.MaterialandMethods
2.1. Animals and Treatment. T h ee x p e r i m e n t a lp r o t o c o lw a s
approved by the Local Bioethical Council of the Medical
University in Lublin. The study was conducted on sexually
mature albino rats of Wistar CRL: (WI) WUBR strain,
obtained from a commercial breeder (Warsaw-Rembertow,
Poland). The animals with the initial body weight of 160–
195g were maintained in stable conditions at 22◦Cw i t ha
12h light/dark cycle and were given standardized granulated
fodder LSM (AGROPOL, Poland).
All the animals were randomly divided into six groups
(n = 8): DOX-doxorubicin 1.5mg/kg; 2T4+ DOX-thyroxin
2.0mg/L and doxorubicin 1.5mg/kg; 0.2T4+ DOX-thyroxin
0.2mg/L and doxorubicin 1.5mg/kg; 2T4-thyroxin 2.0mg/L;
0.2T4-thyroxin 0.2mg/L; the untreated control (Figure 1).
Thyroxin (Sigma, USA) was administered in drinking
water in two doses: 0.2 (0.2T4,0 . 2 T 4+D O X )a n d2 m g / L
(2T4, 2T4+ DOX) throughout the 14 weeks of the experi-
ment. Since the end of the ﬁrst week, doxorubicin (Ebewe,
Austria) was intraperitoneally injected (1.5mg/kg) once a
week for ten weeks in groups DOX, 2T4+ DOX, and 0.2T4+
DOX(Figure 1). The doses for both compounds were chosen
according to the previous data [14, 41, 42]. Two days after
T4 treatment was terminated (experimental day 100) and
animals were sacriﬁced. The blood and heart were collected
during autopsy.
Theheartwaswashedwith20mLofsalinethensectioned
along the interventricular and coronal grove. The left ven-
tricular wall was placed in liquid nitrogen and stored
at −75◦C until the biochemical and molecular analyses
were conducted. The right ventricular wall samples were
ﬁxed in buﬀered 10% formalin and routinely processed
histologically.
2.2. Evaluation of Serum Biochemical Parameters. Serum-
free tetraiodothyronine (FT4) concentration was determined
using a competitive ELISA test (Novatec, Germany) accord-
ing to the manufacturer’s manual, based on the immune
complex formed by the enzyme-labeled antigen and ﬁnal
absorption reading at 450nm with a microwell plate reader
(BIO-TEK XS PowerWave, USA).
Heart cTnI, H-FABP, and BNP concentrations were
assessed in rat serum with ELISA commercial kits as follows:
Life Diagnostic (USA) for cTnI and H-FABP and Assay Pro
(USA) for BNP, where two types of antibodies were used in
the evaluation: antibodies covering microtiter plate and the
secondary antibodies bound to horseradish peroxidase. The
product of the catalytic reaction was spectrophotometrically
detected at 450nm.
Aspartate aminotransferase (AST) activity was deter-
mined by means of the kinetic method with commercial di-
agnos-tic kits (Cormay, Poland). The transfer of the amino
group between L-aspartate and 2-oxoglutarate was catalyzed
by AST and the decrease in NADH absorbance measured at
340nm.Oxidative Medicine and Cellular Longevity 3
2.3. Evaluation of Tissue Markers for Redox Imbalance. The
evaluation of lipid peroxidation product was based on the
malondialdehyde (MDA) concentration in cardiac homoge-
nates. The commercial kit TBARS (Cayman, USA) was used
for the assessment. The concept of the method is based on
the reaction between MDA and thiobarbituric acid at 100◦C
and low pH.
NADPH concentration was determined by the spec-
trophotometric method described in the commercial kit
(Bio Vision, USA). The obtained and frozen cardiac sam-
ples (∼20mg) were homogenized in an extraction buﬀer
provided by the manufacturer and then incubated at 60◦C
in order to decompose NADP particles. The ﬁnal readings
weremadeusingPowerWaveMicroplateSpectrophotometer
(Bio-Tek) at 450nm.
2.4. Evaluation of DNA Oxidative Damage. The commercial
kit (Fermentas, Lithuania) was used for isolation of the
cardiac DNA according to the manufacturer’s manual. The
frozen tissue was pulverized in liquid nitrogen and sus-
pended in TRIS-EDTA (TE) buﬀer. Then the sample was
incubated in the lysis buﬀer at 65◦C. Released DNA was
extracted with the use of chloroform and then precipitated
with the precipitation factor.
DNA oxidative damage in the cardiac muscle was
evaluated by measuring the amount of abasic sites (so-
called AP) with a commercial kit (Dojindo, Japan). The
isolated DNA was labeled with ARP reagent which can
recognizealdehydegroupoftheopenringinAPsitesandcan
combinewithbiotin.Thenbiotin-avidin-speciﬁcconnection
and horseradish peroxidase was used for the colorimetric
detection at 650nm.
2.5. Evaluation of Expression of SERCA2 and RyR2 Proteins.
Cardiac samples were homogenized in 20mM phosphate
buﬀer (pH 7.4; proportions: 0.5g of tissue and 2cm3 of
buﬀer) with a protease inhibitor cocktail (Sigma-Aldrich,
USA) in a homogenizer with a Teﬂon piston (5 min-
utes at 4000rpm). Then, homogenates were centrifuged at
14000rpm at 4◦Cf o r2 0m i n u t e sa n du s e dt oq u a n t i f y
SERCA2 and RyR2 proteins by immunoblotting. Six ran-
domly selected samples were taken from diﬀerent, ran-
domly selected animals in each study group. 20μgo f
protein was loaded in a polyacrylamide gel and 50-minute
electrophoretic separation was performed under reducing
conditions in XCellSureLock apparatus (Invitrogen, USA)
at constant voltage of 200V. After separation, the gel and
the nitrocellulose membrane were placed between two layers
of the ﬁlter paper and put between two electrodes of XCell
II Blot Module electrotransfer apparatus (Invitrogen, USA).
The transfer was conducted for 60 minutes at the constant
voltage of 30V. Blots were developed using Western Breeze
Chromogenic Detection Kit (Invitrogen, USA). Nonspeciﬁc
antibody-binding sites were blocked and the membrane
was incubated in the solution of the primary antibody:
monoclonal mouse antibody against rat SERCA2 protein
(clone 2A7-A1; Aﬃnity BioReagents, USA) or against rat
RyR2 protein (clone 34C; Aﬃnity BioReagents, USA). After
washing, the membrane was incubated with the secondary
Table 1: Concentration (ng/L) of free thyroxin in rats’ serum.
FT4
Control 22.38 ±3.18
2T4 29.77 ±5.65a
0.2T4 21.39 ±4.42
Data presented as mean ± SD; aP<0.05 versus control.
antibody combined with alkaline phosphatase. The last
step was to mark the sites of reaction with antigen by
the reaction of alkaline phosphatase and chromogen. The
relative intensities of bands were quantiﬁed using the 1D
Image Analysis Software program (Kodak, USA), and all the
values were normalized to the intensities of the respective
beta-actin signal that was used as a loading control (Abcam,
USA).
2.6. Preparation of Slides for Histological Evaluation. 4μm
histological slides obtained from paraﬃn blocks were rou-
tinely processed and stained with hematoxylin and eosin
(H&E) as well as using van Gieson’s method.
2.7. Statistical Analysis. The obtained data was statisti-
cally analyzed using STATISTICA 5.0 software. Results are
expressed as mean ± standard deviation (SD). Continuous
data were compared among the experimental groups using
the Kolmogorov-Smirnov test. The statistical signiﬁcance
of diﬀerences between control and the other groups was
evaluated either by t-Student test or U Mann-Whitney test,
and group to group comparisons were made by one-way
ANOVA. The value of P ≤ 0.05 was considered as statistically
signiﬁcant.
3. Results
The level of free thyroxin (FT4) was signiﬁcantly higher in
animals treated with 2mg/L of T4 than in the untreated
control group (Table 1). However, an insigniﬁcant change in
T4 blood level was observed when the animals were treated
with a lower hormone dose (0.2mg/L).
A signiﬁcantly lower concentration of NADPH in the
cardiac muscle was observed only in 0.2T4+D O Xg r o u p
comparedtothecontrolandtothegroupexposedexclusively
to DOX (Table 2). Lipid peroxidation products, MDA, were
also signiﬁcantly higher in 2T4+ DOX group and in 0.2T4+
DOX group when compared to the control group. A similar
eﬀect was observed in animals receiving a higher dose of
thyroxin (Table 2). Insigniﬁcant diﬀerences in the oxidative
DNA damage in the cardiac muscle were revealed in all
examined groups (Table 2). It is worth mentioning that a
lowest number of abasic sites was observed in the group
treated only with DOX, while the highest was found in the
group exposed to DOX and a higher dose of T4 (2T4+DO X ) .
There were insigniﬁcant changes in SERCA2 protein
level in any tested group comparing to the control and
between DOX and T4+ DOX groups. When compared to
the untreated control, a 25 and 16% decrease of SERCA2
protein level was found in 0.2T4+D O Xa n d2 T 4+D O X4 Oxidative Medicine and Cellular Longevity
Table 2: Concentration of NADPH (nmol/g tissue), MDA (nmol/g tissue), and the number of abasic sites in genomic DNA (AP/100kbp) in
the cardiac muscle.
NADPH MDA AP in gDNA
Control 19.95 ±5.22 .37 ±0.39 7.34 ±2.84
DOX 24.53 ±6.79 2.30 ±0.66 6.56 ±1.99
2T4+D O X 1 6 .12 ±5.30 3.75 ±0.66a,b 9.65 ±3.79
0.2T4+D O X 9 .27 ±1.72a,b 3.13 ±0.65a,b 6.84 ±3.29
2T4 22.13 ±5.25 3.84 ±1.45a 8.46 ±5.48
0.2T4 18.10 ±5.73 3.03 ±0.94 6.29 ±1.51
Data presented as mean ± SD; aP<0.05 versus control; bP<0.05 versus DOX.
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Figure 2: (a) Representative Western blot analysis for SERCA2
protein in cardiac muscle homogenates. Beta-actin is shown as a
loading control. (b) Densitometric analysis (mean ± SD) of total
SERCA2 content expressed as percent changes with respect to the
control group, which was established at 100%.
groups, respectively (Figure 2). Less intensive changes were
noted in the group exposed exclusively to DOX. However, in
animals receiving only the lower dose of T4, a 10% increase
of SERCA2 protein concentration was revealed.
The level of RyR2 protein was the lowest in 2T4+D O X
group (13% of the control), and it was signiﬁcantly diﬀerent
from the control and from the DOX group (Figure 3). A
signiﬁcant decrease of the parameter was also detected in
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Figure 3: (a) Representative Western blot analysis for RyR2 protein
in cardiac muscle homogenates. Beta-actin is shown as a loading
control. (b) Densitometric analysis (mean ± SD) of total RyR2
content expressed as percent changes with respect to the control
group, which was established at 100%. aP<0.05 versus control;
bP<0.05 versus DOX.
groups: DOX (41%) and 0.2T4+ DOX (71%) as compared
to the control.
A signiﬁcant decrease of BNP level was found in all drug-
exposed groups when compared with the untreated control
(Table 3). The most signiﬁcant diﬀerences (about 50%) were
observed in 2T4+D O Xa n d2 T 4 groups.Oxidative Medicine and Cellular Longevity 5
Table 3: Concentration (ng/mL) of BNP, H-FABP and cTnI, and activity (IU/L) of AST in rats’ serum.
BNP H-FABP cTnI AST
Control 0.309 ±0.02 24.07 ±2.49 2.68 ±0.69 138.14 ±38.40
DOX 0.193 ±0.08a 5.90 ±1.34a 0.78 ±0.63a 114.40 ±56.79
2T4+D O X 0 .153 ±0.06a 4.50 ±0.43a 0.57 ±0.66a 80.83 ±30.79a
0.2T4+D O X 0 .254 ±0.04a 19.29 ±4.36 2.64 ±1.54 113.67 ±23.37
2T4 0.184 ±0.04a 5.81 ±1.13a 0.83 ±0.73a 150.83 ±14.62
0.2T4 0.236 ±0.01a 21.85 ±3.87 3.12 ±1.09 145.33 ±17.71
Data presented as mean ± SD; aP<0.05 versus control.
Table 4: Histological features of the cardiac muscle in experimental and control groups.
Interstitial Perivascular ﬁbrosis Cardiomyocytes Inﬂammation
ﬁbrosis edema vacuolisation irregular cytoplasm staining
Control 2 — 1 — — 1
DOX 2 — 2 1 3
2T4+D O X 4 — 1 — 3 5
0.2T4+D O X 4 — — 3 2 3
2T4 33 — — 1 1
0.2T4 28 — — — 3
Samples from all rats in all experimental and control groups were evaluated (n = 8/group). A single animal may be represented more than once in the listing
of individual histological changes.
There was an insigniﬁcant increase of H-FABP level in all
testedanimalgroupscomparedtothecontrol.InDOX,2T4+
DOX,and2T4 group,signiﬁcantlylowerconcentrationswere
observed (Table 3).
The level of the concentration of cTnI in three groups of
DOX,2T4+DO X,and2T 4 wassigniﬁcantlylowerthaninthe
control and it was similar in all those groups.
AST activity was signiﬁcantly decreased only in 2T4+
DOX group when compared with the untreated control.
Histological cardiac changes were focal and accidentally
observed (Table 4). Necrosis was not revealed in any of the
examined slides, but other local changes with minimal or
low intensity were revealed in all groups. In some cases,
a small area with a subendomyocardial and perivascular
ﬁbrosis was found (Figure 4(a)). Interstitial connective tissue
edema was observed in all rats treated with a lower dose of
T4 and in three rats from 2T4 group (Figure 4(b)). Single
animals from the groups of DOX and 0.2T4+D O Xr e v e a l e d
focal vacuolization of sparse cardiomyocytes (Figure 4(c)).
Several samples from diﬀerent groups show focal irregular
sarcoplasm staining. Small local accumulations of mononu-
clear cells were seen in all groups, while a large inﬂammatory
inﬁltration without evidence of the cardiomyocyte damage
was found only in single cases in DOX (n = 2), 2T4+D O X
(n = 1), and 0.2T4+D O Xg r o u p s( n = 1) (Figure 4(d)).
4. Discussion
As it was pointed out in the introduction, there are two
principal mechanisms responsible for anthracycline car-
diotoxicity: contractility dysfunction [8–10] and oxidative
stress [6, 7], which might be inﬂuenced by an abnormally
high level of T4 blood.
To ﬁnd out if T4 concentrations in the supplemented diet
were proper for our studies, we assessed free tetraiodothyro-
nine FT4 level in the blood. A lower dose of FT4 had no eﬀect
on FT4 blood concentration, which is presumably caused by
the adaptive mechanism based on the restriction of thyroxin
synthesis by the thyroid. However, a higher dose of T4 caused
a signiﬁcant increase in FT4 blood concentration; therefore,
the tested doses were chosen properly.
The studies revealed that T4 in a higher dose causes an
adverse interaction with DOX referring to the contractile
protein RyR2 and lipid peroxidation. There was an insignif-
icant adverse eﬀect of T4 on the necrosis of cardiomyocytes
and cardiac morphology in rats receiving DOX.
The eﬀect of DOX on RyR2 is consistent with the results
obtained by Arai et al. [40], where rabbits were treated with
2.5mg/kg of DOX every week for eight weeks and a lower
expression of RyR2 was accompanied by a lower protein
amount 8 weeks after the ﬁnal injection. Those authors had a
similar observation referring to SERCA2 mRNA and protein.
However, in our studies, in the group where 1.5mg/kg of
DOX was administered to rats for ten weeks, a lower but
insigniﬁcant concentration of SERCA2 protein was noted
in all DOX-exposed groups. It is especially important since
the protein level was increased three weeks after DOX
administration was completed. Such data indicate that the
levelofRyR2proteinwasconstantlylowerseveralweeksafter
the ﬁnal dose of DOX and the question is if these changes are
irreversible.
Both SERCA2 and RyR2 are controlled by thyroid hor-
mones [13, 14]. Our study revealed a higher RyR2 protein6 Oxidative Medicine and Cellular Longevity
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Figure 4: Selected cardiac abnormalities found among the treated animals. (a) Perivascular ﬁbrosis in a rat treated with doxorubicin
1.5mg/kg (group DOX, van Gieson; objective mag. ×10). (b) Interstitial connective tissue edema in a rat treated with thyroxin dose of
0.2mg/L (group 0.2T4; H&E objective mag. ×10). (c) Focal vacuolization of sparse cardiomyocytes in a rat treated with 0.2mg/L of thyroxin
and 1.5mg/kg of doxorubicin (group 0.2T4 +D O X ;H & E ,o b j e c t i v em a g .×20). (d) Sparse and small accumulations of mononuclear cells in
myocardium in a rat treated with 0.2mg/L of thyroxin and 1.5mg/kg of doxorubicin (group 0.2T4 +D O X ;H & E ,o b j e c t i v em a g .×20).
level in rats after thyroxin treatment, with SERCA2 level also
being higher but statistically insigniﬁcant in rats treated with
a lower dose of T4. These results are similar to Arai et al. [14]
study, where rats were administered a daily dose of 200μg/kg
of T4 for 4 and 8 weeks, which is comparable to the dose
used in the present study. An over 100% increase in SERCA2
mRNA concentration was detected in the study by Ojamaa et
al. [43], where rats were treated with T4 only for 72 hours. It
seems that both DOX and thyroxin modulate the synthesis
of RyR2 and SERCA2 by other mechanisms of regulation
[9, 10, 13, 14].
Moreover,theobtainedresultsconﬁrmedthatDOXleads
to decrease, while 2T4 to increase in the level of RyR2 when
compared to the control group. On the basis of these eﬀects,
it might be expected that an abnormally high level of T4
should normalize RyR2 concentration disturbed by DOX.
Such an action was observed when DOX was coadministered
with a low dose of T4. However, a higher dose of T4 in rats
receiving DOX caused a much higher decrease in RyR2 level
than it was in rats administered with DOX alone. Such data
may indicate an adverse clinical implication in hyperthyroid
individuals treated with DOX.
Furthermore, iodothyronine hormones and DOX not
only aﬀect RyR2 and SERCA2 level but may also inﬂuence
their function via the redox dependent mechanism. There
is increasing evidence that the Ca2+ transport activity
of RyR2 and SERCA2 is redox dependent [15–18]. Both
iodothyronine hormones and DOX aﬀect NADPH cell bal-
ance, which is seemingly paradoxically involved in oxidative
stress generation and at the same time the antioxidative
defense [23, 28, 29, 36].
Thehypothesisthatoxidativestressisthemostimportant
mechanism in long-term cardiotoxicity of anthracyclines
leading to heart failure is widely accepted [7, 8]. Because
lipid and DNA oxidative damage markers reﬂect changes
in oxidants-antioxidants balance, we assessed the inﬂuence
of the studied drugs on both marker levels. However, in
DOX-exposed group of the present study, where the organ
samples were examined three weeks after the last dose of
DOX, a lack of oxidative stress—tested on the basis of lipids
and DNA oxidation products—was found. According to the
literature, oxidative stress markers are elevated a short time
after drug administration (hours or even days) because DOX
is still present in the tested tissue [35, 44, 45]. In these
cases, oxidative stress in the heart is the direct eﬀect of DOX
participating inthe transferofelectronsfromNADPHtoO2,
whichresultsinsuperoxideoverproduction.However,itdoes
not explain the ROS-dependent mechanism of heart failure
when clinical symptoms are observed several years after
DOX-administration was completed. According to recent
suggestions, ROS produced during DOX redox metabolism
initiates early oxidative changes in the mitochondrial DNA
(mtDNA) [46]. In that period, the symptoms of oxidative
stress may be reduced parallel to DOX excretion from theOxidative Medicine and Cellular Longevity 7
body. However, an increase of mtDNA damages may result
in a mutation leading to the synthesis of mitochondrial
proteins with defects causing disorders in the mitochondrial
physiology [47]. As a ﬁnal result, ultrastructural changes
through the mitochondrial electron chain of cardiomyocytes
lead to mtDNA disorders [48–50] and to an increase of ROS
production [46, 51]. Such a cycle is repeated constantly and
noclinicalsymptomsareobservedinthebeginningbutwhen
mitochondria fail, a clinically detected heart failure may
occur. Therefore, the explanation that markers indicating
oxidative stress are seen at the early stage when DOX is
present in the tissues and in the late period whendisorders in
electron transfer are serious seems reasonable. Referring to a
recent study, no signs of oxidative stress in rats treated with
DOX alone may be explained by the fact that within 3 weeks
after the last dose of DOX the drug was removed from the
body. However, the time of the experiment was too short to
reveal the cumulative, oxidative eﬀects of the mitochondrial
DNA damage. The studies published by Robinson et al. [52],
where rats were treated with 2mg/kg of DOX for 13 weeks,
conﬁrmed that oxidative stress is not observed even 14 and
19 weeks after the ﬁnal dose of the drug.
However, T4-supplementeddietinratstreatedwithDOX
leadstoanincreaseoflipidperoxidationproductscomparing
to the group administered with DOX alone. It is the evidence
that T4 is responsible for oxidative stress in the heart of rats
treated with DOX. It should be noticed that in the groups of
T4 +D O X ,R O Sa ﬀects lipids but not DNA. Similar to our
results, there was no DNA damage after THs administration
although lipid peroxidative changes were observed [25, 26].
The absence of DNA damage might be explained by the
fact that ROS are neutralized by intracellular antioxidants
before the nucleus is reached. Higher susceptibility of lipids
to oxidative stress may form a protective barrier against
DNA oxidative damages. Genomic DNA might be protected
better than lipids due to histone binding, which makes it
less susceptible to damage or abnormalities, with DNA being
repaired faster than other molecules.
NADPH level was signiﬁcantly lower in the heart of rats
from 0.2T4+ DOX (as opposed to 2T4+D O X )g r o u pc o m -
pared to the control and DOX groups. This ﬁnding indicates
that the observed changes are dose related. In the presence
of DOX, NADPH is a source of ROS generation and at the
sametimeitisakeyfactorintheantioxidativedefencecaused
by ROS [8, 53, 54], whereas T4 intensiﬁes NADPH con-
sumption,whichisduetostimulatedmetabolism.Moreover,
because of transcriptional activation of same genes respon-
sible for the synthesis NADPH-dependent enzymes (e.g.,
P450R, NOS, and NADPH oxidase [23, 28, 29, 36]), T4 may
intensify NADPH consumption. It should be stressed that at
the same time T4 activated genes responsible for NADPH
synthesis, that is, glucose-6-phosphate dehydrogenase, 6-
phosphogluconate dehydrogenase, and malate enzyme [30–
32], but this mechanism is insuﬃc i e n tt ok e e pN A D P Ho n
the normal level in 0.2T4+D O Xg r o u p .H o w e v e r ,w h e n
rats were administered a higher dose of thyroxin (2T4+
DOX group) no diﬀerences in NADPH level comparing
to the control and DOX groups were found. This may
suggest that the synthesis of NADPH controlled by T4 is
suﬃcienttocompensatethestressstimulatedbytheactionof
DOX.
On the other hand, the oxidative damage of lipid
membranes may result in the death of cardiomyocytes and
remodeling of the heart muscle [55]. Therefore, cardiac
morphology and various biochemical markers were eval-
uated. There was no eﬀect of T4 on cardiac histology in
rats treated with DOX. Biochemical observations based on
cTnI, H-FABP, and BNP, serum markers, or a detailed
analysis of histological slides did not indicate necrosis of
cardiomyocytes in any of the tested group. The obtained
data suggest that oxidative stress estimated on the basis
peroxidation of lipids products seen in both groups of T4+
DOX is insuﬃcient to elicit necrosis.
The level of H-FABP, cTnI, and BNP was even lower
in the serum of rats treated with a higher dose of T4 and
DOX separately or together as compared to the control.
Similar results referring to H-FABP after DOX treatment
were presented by Sayed-Ahmed [56], who administered the
drug in a cumulative dose of 18mg/kg. There were a lot
of studies conﬁrming that BNP is aﬀected by DOX [57–60]
and T4 [61, 62]. BNP is considered to be a marker diastolic
dysfunction of heart ventricles [56, 59]. Presumably, a DOX-
related low level of RyR2, cTnI, H-FABP, and BNP—key
proteins in contractile activity—may depend partly on the
unspeciﬁc manner of proteasome degradation, which was
conﬁrmed in recent studies by An et al. [63].
In conclusion, the present studies revealed that an abnor-
mally high level of T4 was responsible for the heart redox
imbalance, oxidative stress, and RyR2 protein reduction in
rats treated with DOX. Further studies on the heart function
should be continued to assess if T4 might be considered as an
additional risk factor in anthracycline cardiotoxicity.
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